Chemed Corporation
CHE
$595.74
$1.390.23%
| Weiss Ratings | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | B | |||
| Rating Factors | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.34 | |||
| Price History | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.15% | |||
| 30-Day Total Return | 10.09% | |||
| 60-Day Total Return | 7.90% | |||
| 90-Day Total Return | -0.01% | |||
| Year to Date Total Return | 12.94% | |||
| 1-Year Total Return | -8.04% | |||
| 2-Year Total Return | 17.22% | |||
| 3-Year Total Return | 24.40% | |||
| 5-Year Total Return | 53.85% | |||
| 52-Week High % Change | -9.21% | |||
| 52-Week Low % Change | 16.06% | |||
| Price | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $654.62 | |||
| 52-Week Low Price | $512.12 | |||
| 52-Week Low Price (Date) | Dec 23, 2024 | |||
| 52-Week High Price (Date) | Mar 15, 2024 | |||
| Valuation | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 8.70B | |||
| Enterprise Value | 8.66B | |||
| Price/Earnings (TTM) | 29.84 | |||
| Earnings Per Share (TTM) | 19.92 | |||
| Earnings Per Share Growth | 11.14% | |||
| Price/Earnings To Growth | 2.68 | |||
| Price/Sales (TTM) | 3.66 | |||
| Price/Book (Q) | 7.73 | |||
| Enterprise Value/Revenue (TTM) | 3.56 | |||
| Price | $595.74 | |||
| Enterprise Value/EBITDA (TTM) | 20.35 | |||
| Enterprise Value/EBIT | 23.61 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 14.99M | |||
| Dividend Yield | 0.32% | |||
| Div. Per Share (Most Recent) | $0.50 | |||
| Dividend Per Share (TTM) | $1.90 | |||
| Payout Ratio (TTM) | 8.97% | |||
| Dividend Per Share (Most Recent) | $0.50 | |||
| Company Info | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 513 762 6690 | |||
| Address | 255 East Fifth Street Cincinnati, OH 45202-4726 | |||
| Website | www.chemed.com | |||
| Country | United States | |||
| Year Founded | 1970 | |||
| Profitability | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 15.09% | |||
| Profit Margin | 12.42% | |||
| Management Effectiveness | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 13.75% | |||
| Return on Equity | 27.12% | |||
| Income Statement | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.43B | |||
| Total Revenue (TTM) | 2.43B | |||
| Revenue Per Share | $162.17 | |||
| Gross Profit (TTM) | 854.35M | |||
| EBITDA (TTM) | 425.69M | |||
| EBIT (TTM) | 366.94M | |||
| Net Income (TTM) | 302.00M | |||
| Net Income Avl. to Common (TTM) | 302.00M | |||
| Total Revenue Growth (Q YOY) | 9.23% | |||
| Earnings Growth (Q YOY) | 0.30% | |||
| EPS Diluted (TTM) | 19.92 | |||
| EPS Diluted Growth (Q YOY) | 2.13% | |||
| Balance Sheet | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 178.35M | |||
| Cash Per Share (Q) | $11.90 | |||
| Total Current Assets (Q) | 394.75M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.12B | |||
| Current Ratio (Q) | 1.382 | |||
| Book Value Per Share (Q) | $76.87 | |||
| Total Assets (Q) | 1.67B | |||
| Total Current Liabilities (Q) | 285.70M | |||
| Total Debt (Q) | 140.84M | |||
| Total Liabilities (Q) | 549.58M | |||
| Total Common Equity (Q) | 1.12B | |||
| Cash Flow | CHE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -143.91M | |||
| Cash from Financing (TTM) | -359.19M | |||
| Net Change in Cash (TTM) | -85.61M | |||
| Levered Free Cash Flow (TTM) | 283.41M | |||
| Cash from Operations (TTM) | 417.50M | |||
